8 December 2019 - It feels like ‘bugs under the skin’ 24/7, but a new drug that offers hope to sufferers of eczema has been knocked back by the government subsidy program because it is too expensive. 

Now a new campaign is launching to ‘Save our Skin’ and highlight the terrible plight of the condition.

Dupixent, or dupilumab, is a biologic drug that blocks the immune system reaction that causes the chronic inflammatory response but it costs as much as $1,600 a month. The drug has twice been knocked back for listing on the PBS due to its expense.

Read Daily Telegraph article